readi pounc initi coverag buy price target
promis futur nerlynx initi coverag puma
buy rate price target leverag
sale growth estim approv market nerlynx neratinib
p/e-bas valuat approach nerlynx market extend
adjuv treatment adult patient earli stage human epiderm
adjuv herceptin trastuzumab -base therapi administ
daili oral avail irrevers kinas inhibitor nerlynx
approv fda juli ema septemb
 receiv adjuv treatment
annual sale disappoint patient durat drug
stunt earli discontinu due incid
grade diarrhea effort expand label commerci
market nerlynx also evalu compani metastat
breast cancer nda submit metastat
breast cancer brain metastas breast cancer
solid tumor importantli compani sign sever licens deal
market nerlynx outsid posit
impact bottom line
diarrhea control patient discontinu nerlynx
earli treatment due high incid diarrhea focu
fda meet led approv nerlynx
phase extenet studi extenet double-blind placebo-
control studi nerlynx versu placebo adjuv treatment
herceptin women earli stage breast cancer efficaci
posit trial evidenc two year follow-up data
extenet frequent observ advers event nerlynx-
treat patient diarrhea grade diarrhea one patient
grade diarrhea observ nerlynx-tr
patient patient receiv nerlynx trial receiv
prophylaxi anti-diarrhea agent prevent nerlynx-rel
diarrhea address diarrhea issu phase control studi
initi evalu diarrhea prophylaxi studi includ
cohort patient treat prohphylaxi loperamid loperamid
plu budesonid colestipol plu loperamid interim result
trial demonstr prophylaxi treatment deliv earli dose
lower incid grade diarrhea patient discontinu
studi initi underway dose escal cohort
ad octob announc fda
approv label updat nerlynx includ prophylact treatment
loperamid plu budesonid interim result control
show grade diarrhea patient treat nerlynx dose
escal mandatori diarrhea prophylaxi cohort
median cumul durat grade diarrhea two day
patient cohort discontinu due diarrhea
believ dose escal strategi easi adopt doctor
prefer patient state result confer
call method alreadi appear gain traction dose
escal strategi would hurt near-term sale believ short-
term loss off-set long-term gain patient could
potenti stay drug much longer seen sinc
launch
definit distribut analyst rate analyst certif disclosur pleas refer page report
metastat opportun potenti believ metastat breast cancer sizeabl opportun compani
capit nerlynx accord american cancer societi estim new case invas
breast cancer women along new case ductal carcinoma situ dci expect diagnos
 women averag risk develop breast cancer lifetim approxim
breast cancer tumor over-express human epiderm growth factor receptor protein market size
third-lin metastat breast cancer approxim patient patient fourth-lin standard-of-
care metastat breast cancer first-lin set taxan plu herceptin perjeta pertuzumab second-
line standard-of-car kadcyla puma nala trial assess nerlynx plu xeloda capecitabin versu tykerb
plu xeloda treatment third- later-lin metastat breast cancer data show
six month nerlynx plu xeloda versu six month tykerb plu xeloda use pre-specifi mean
analysi mean nerlynx arm month month tykerb plu xeloda os
month nerlynx plu xeloda versu month tykerb plu xeloda puma submit supplement nda third-lin
metastat breast cancer fda june accept septemb anticip pdufa date
late april puma phase trial evalu nerlynx plu kadcyla treatment metastat breast
cancer patient trial on-going enrol data expect puma also on-going phase studi
call tbcrc evalu nerlynx monotherapi combin therapi agent treatment
metastat breast cancer patient brain metastas
larg opportun abroad puma puma numer licens deal partnership foreign compani
importantli puma also right double-digit royalti sale nerlynx approv territori foreign partner
notabl partner puma pierr fabr privat grant develop commerci right within europ
exclud russia ukrain within part africa pierr fabr also right nerlynx middl east south
africa sudan turkey amend agreement per agreement pierr fabr puma would entitl
receiv signific double-digit royalti high nerlynx sale territori pierr fabr
right pierr fabr expect launch nerlynx germani austria launch rest europ
expect take place puma also enter partnership greater china canada israel latin
south america australia south east asia puma signific opportun revenu growth drop
bottom line due strateg agreement
valuat base price target price-to-earnings multipl ep estim discount
discount rate use well compani wacc believ price-to-earnings multipl averag
peer appropri project compani turn profit cash level million end
enabl compani reach profit without revisit capit market
risk commerci regulatori develop manufactur financi liabil intellectu properti
initi coverag stock buy rate price target
puma biotechnolog compani focus develop commerci oncolog treatment
compani found headquart lo angel california initi public
offer puma market drug call nerlynx neratinib approv fda
juli extend adjuv treatment adult patient earli stage breast cancer follow
adjuv herceptin-bas therapi compani retain full commerci right drug june
compani amend loan agreement oxford financ replac million loan
loan million compani report million cash cash equival balanc
sheet outstand debt million end believ cash enabl
compani reach profit without revisit capit market
nerlynx daili oral avail irrevers kinas inhibitor studi multipl indic
includ metastat breast cancer metastat breast cancer brain metastas lung
cancer cervic cancer solid tumor octob puma announc nerlynx
receiv approv label expans extend adjuv treatment earli breast cancer
label expans includ safeti data compani phase control trial evalu anti-
diarrhea prophylaxi dose escal reduct nerlynx associ diarrhea nerlynx label
supplement detail prophylact imodium loperamid combin budesonid help
doctor patient order help better understand combat diarrhea associ nerlynx
doctor current prescrib diarrhea prophylaxi patient receiv nerlynx
incid diarrhea associ treatment discontinu impact sale puma
announc septemb supplement nda base result phase
nala trial accept fda extend nerlynx treat patient third-lin metastat
breast cancer basket trial call summit underway evalu nerlynx varieti
puma network six specialti pharmaci provid nerlynx directli patient puma also
separ specialti distribut in-hous dispens channel without need send prescript
specialti pharmaci novemb compani sale rep seven sale vacanc
compani previous ad nurs nurs educ team help physician practic educ
side effect manag nurs
puma multipl key near term upcom mileston could lead improv revenu higher
stock price mileston includ nerlynx launch germani austria
launch rest europ pdufa date metastat breast cancer late
april updat nerlynx plu faslodex fulvestr plu herceptin data summit trial
san antonio breast cancer symposium sabc pre-nda meet sometim
basi summit trial result interim result control publish
medic journal
extend adjuv ebc launch germani austria
data publish medic journal
pre-nda meet hr breast
cancer cervic cancer
extend adjuv ebc launch rest europ
compani report wainwright research
bullish puma import reason list
lower incid diarrhea could key improv sale
nerlynx potent irrevers tyrosin kinas inhibitor tki block signal transduct
epiderm growth factor receptor egfr approv
extend adjuv treatment adult patient early-stag breast cancer follow adjuv
herceptin-bas therapi also grant market author european commiss
extend adjuv treatment adult patient early-stag hormon receptor-posit hr
breast cancer less one year complet prior adjuv herceptin-bas treatment
puma in-licens global develop commerci right nerlynx oral
intraven rate tykerb lapatinib novarti nv rate
similar mechan action select profil tykerb revers tki approxim
earli stage breast cancer patient eu receiv adjuv
treatment annual sale nerlynx expect incid diarrhea led
drug discontinu issu address compani on-going phase control
approv launch nerlynx approv fda juli follow posit fda
oncolog drug advisori committe odac meet may odac vote
recommend approv nerlynx extend adjuv treatment earli stage breast cancer
base review clinic develop program includ trial breast cancer
repres approxim patient year experi focu meet phase
extenet studi extenet trial double-blind placebo-control studi nerlynx versu placebo
adjuv treatment herceptin women earli stage breast cancer enrol
patient center countri earli stage breast cancer undergon surgeri
adjuv treatment herceptin complet surgeri adjuv treatment herceptin
patient random receiv extend adjuv treatment either per day nerlynx
match placebo period one year patient follow recurr diseas dci
death period two year random trial inclus criteria extenet trial
patient need tumor use local assess pre-defin subgroup
trial patient central test perform tumor well patient
nerlynx arm trial node posit patient hr
patient placebo arm trial node posit patient
hr
june puma submit ema nerlynx extend adjuv treatment
patient early-stag breast cancer receiv prior adjuv herceptin-bas therapi
base extenet trial nerlynx grant market author septemb
european commiss extend adjuv treatment adult patient earli stage hr
breast cancer less one year complet prior adjuv herceptin base
therapi compani partner drug europ
posit phase data report juli puma announc top line result extenet
trial nerlynx extend adjuv treatment earli stage breast cancer data
trial present oral present american societi clinic oncolog annual
meet june publish on-line lancet oncolog februari studi hit
primari endpoint invas diseas free surviv idf demonstr statist signific
rel reduct risk invas diseas recurr death nerlynx versu placebo hr
 within two year treatment idf rate nerlynx arm
idf rate placebo arm benefit robust patient subgroup
secondari endpoint trial idf includ ductal carcinoma situ idfs-dci result
trial demonstr treatment nerlynx result reduct risk diseas
recurr includ dci death versu placebo hazard ratio idfs-dci
rate nerlynx arm idfs-dci rate placebo arm
cutoff date central test perform patient extenet
trial pre-defin subgroup patient whose tumor central confirm
nerlynx treatment result reduct risk invas diseas recurr death versu
placebo hazard ratio idf rate central confirm patient
nerlynx arm idf rate central confirm patient placebo arm
patient trial whose tumor central confirm result
trial demonstr treatment nerlynx result reduct risk diseas recurr
includ dci death versu placebo hazard ratio idfs-dci rate
central confirm patient nerlynx arm idf rate central confirm
patient placebo arm
preliminari result pre-defin subgroup patient hr diseas nerlynx treatment result
reduct risk invas diseas recurr death versu placebo hazard ratio
idf rate nerlynx arm idf rate placebo arm
absolut differ patient trial whose tumor central
confirm result trial demonstr treatment nerlynx result reduct
risk invas diseas recurr death hazard ratio idf rate
central confirm patient nerlynx arm idf rate central
confirm patient placebo arm
solid five-year extenet data septemb puma present updat data extenet trial
european societi medic oncolog esmo congress madrid spain data
repres predefin five-year idf analysi follow-up primari two-year idf analysi
phase extenet trial result show median follow year treatment
nerlynx result reduct risk invas diseas recurr death versu placebo hazard
ratio five-year idf rate nerlynx arm idf rate
placebo arm secondari endpoint trial idfs-dci treatment nerlynx
result reduct risk diseas recurr includ dci death versu placebo hazard
ratio five-year idfs-dci rate nerlynx arm five-year
idfs-dci rate placebo arm pre-defin subgroup patient hr diseas
result trial demonstr treatment nerlynx result reduct risk
invas diseas recurr death versu placebo hazard ratio five-year idf
rate nerlynx arm five-year idf rate placebo arm
pre-defin subgroup patient hr- diseas result trial demonstr treatment
nerlynx result hazard ratio
diarrhea concern maximum toler dose nerlynx qd qd
dose limit toxic dlt grade diarrhea mention launch nerlynx
impact diarrhea associ drug present report
frequent observ advers event nerlynx-tr patient diarrhea
patient experienc grade diarrhea approxim nerlynx-tr patient
experienc grade diarrhea one patient grade diarrhea diarrhea tend
transient median cumul durat grade diarrhea five day phase trial
occur commonli first cours therapi extenet studi patient treat
nerlynx requir dose reduct patient discontinu treatment due diarrhea
studi protocol mandat anti-diarrh prophylaxi grade diarrhea occur
patient placebo group complianc rate post launch suffer due diarrhea
elabor later section structur high dose regimen loperamid prophylaxi given
one two cycl introduc better manag diarrhea side effect nerlynx-induc
diarrhea occur earli cours treatment phase control studi conduct exact
set extenet investig effect anti-diarrh prophylaxi loperamid alon
combin budesonid colestipol colestid prevent nerlynx-associ diarrhea
puma report clinic data sever trial demonstr use high
dose prophylact loperamid greatli reduc rate grade diarrhea nerlynx grade
diarrhea rate rang studi high dose loperamid prophylaxi use
barcena carlo et al effect prophylaxi neratinib dose escal neratinib-associ diarrhea
toler patient early-stag breast cancer phase ii control trial american societi clinic
phase control trial seek address diarrhea puma initi control trial
intern open-label phase studi use loperamid prophylaxi without agent
reduct nerlynx-associ diarrhea primari endpoint incid grade diarrhea
trial expand studi dose escal nerlynx
american associ cancer research annual meet poster present
entitl effect ad budesonid colestipol loperamid prophylaxi nerlynx-associ
diarrhea patient earli stage breast cancer control trial present
control trial patient earli stage breast cancer complet herceptin-bas
adjuv therapi receiv nerlynx daili period one year high dose loperamid prophylaxi
given first cycl day treatment initi loperamid dose use day
day day protocol later amend simplifi
regimen day day need thereaft control trial
initi expand includ two addit cohort one cohort receiv combin loperamid
budesonid cohort receiv combin loperamid plu colestipol budesonid
local act corticosteroid puma believ target inflamm identifi preclin model
nerlynx-induc diarrhea colestipol bile acid sequestr compani believ target bile
acid malabsorpt also seen preclin model nerlynx-induc diarrhea later
addit cohort low start dose nerlynx follow dose escal first month
nerlynx treatment ad fourth cohort use anti-diarrhea drug mandatori
prophylaxi dose escal start nerlynx per day first week per week
second week per week start third week continu end treatment
figur interim control data show incid grade diarrhea declin anti-diarrhea
ibrahim et al effect ad budesonid colestipol loperamid prophylaxi neratinib-associ
diarrhea patient early-stag breast cancer control trial american associ cancer
interim analysi trial present poster includ total patient receiv
nerlynx plu loperamid prophylaxi patient take origin dose patient take
modifi dose patient receiv nerlynx plu loperamid prophylaxi two cycl
budesonid one cycl patient receiv nerlynx plu loperamid prophylaxi one cycl
colestipol one cycl interim result trial show incid grade diarrhea
patient receiv loperamid prophylaxi incid grade diarrhea
patient receiv combin loperamid plu budesonid incid
grade diarrhea patient receiv combin loperamid plu colestipol
current on-going nerlynx studi puma institut use anti-diarrhea prophylaxi first
cycl treatment order continu reduc nerlynx-rel diarrhea patient receiv
loperamid prophylaxi median number grade diarrhea episod per patient one
median cumul durat grade diarrhea day discontinu nerlynx due
control data recent data control present
poster present entitl effect prophylaxi neratinib dose escal neratinib-associ
diarrhea toler patient early-stag breast cancer phase ii control trial
data show prevent strategi reduc incid grade diarrhea
primari studi endpoint compar extenet trial importantli grade diarrhea
report control studi sever grade grade diarrhea use prophylaxi
appear acut self-limit manag note studi still on-going
novemb april patient enrol control site
interim analysi poster includ patient receiv nerlynx plu loperamid prophylaxi
patient receiv nerlynx plu loperamid prophylaxi cycl budesonid one cycl
patient receiv nerlynx plu loperamid prophylaxi one cycl colestipol one cycl
patient receiv colestipol one cycl loperamid need patient receiv
dose escal regimen nerlynx
incid grade diarrhea patient receiv loperamid
discontinu nerlynx due diarrhea median cumul durat grade diarrhea day
combin loperamid plu budesonid incid grade diarrhea
discontinu nerlynx due diarrhea median cumul durat grade diarrhea day
combin loperamid plu colestipol incid grade diarrhea
discontinu nerlynx due diarrhea median cumul durat grade diarrhea
day colestipol loperamid need cohort incid grade diarrhea
discontinu nerlynx due diarrhea median cumul durat grade diarrhea
day cohort lastli opinion importantli patient receiv
antidiarrh drug mandatori prophylaxi dose escal nerlynx first month
incid grade diarrhea discontinu nerlynx due diarrhea impress
improv opinion second dose escal cohort evalu nerlynx per day two
week per day week per day thereaft recent start enrol
patient safeti popul data cut-off median cumul durat grade
diarrhea day addit data control trial expect san antonio
figur incid treatment-emerg diarrhea control phase trial worst grade
barcena carlo et al effect prophylaxi neratinib dose escal neratinib-associ diarrhea
toler patient early-stag breast cancer phase ii control trial american societi clinic
figur characterist treatment-emerg diarrhea control
barcena carlo et al effect prophylaxi neratinib dose escal neratinib-associ diarrhea
toler patient early-stag breast cancer phase ii control trial american societi clinic
octob announc fda approv label updat nerlynx includ
prophylact treatment loperamid plu budesonid approv label updat base upon
data interim safeti result phase control trial interim result referenc
label updat show addit prophylact treatment loperamid plu budesomid reduc
discontinu rate due nerlynx-associ diarrhea versu loperamid alon
grade diarrhea shown patient receiv loperamid plu budesonid versu
patient receiv loperamid alon
diarrhea issu commerci set patient discontinu advers
impact nerlynx sale due tendenc patient discontinu treatment earli typic first
month greatli reduc potenti revenu per patient nerlynx achiev
note nerlynx launch juli
compani report wainwright research
label nerlynx includ data loperamid arm control trial last
month alreadi mention fda approv label expans includ data
loperamid plu budesonid arm control trial inclus loperamid plu budesonid
combin could help doctor address diarrhea reduc discontinu data dose
escal cohort control trial yet complet believ data look
promis oncologist familiar dose escal treat patient patient would like
appreci need one prescript instead two three dose escal cohort show
lowest rate patient discontinu thu far control trial compani notic
increas percentag new prescript start lower dose nerlynx believ
indic doctor recommend treatment puma state patient start
reduc dose believ number rose octob
figur percentag patient start nerlynx reduc dose fewer pill per day
puma surmis lower number bottl sold versu may impact
new patient start nerlynx lower dose well discontinu patient start
lower dose would get less refil first quarter start treatment note bottl
nerlynx tablet full dose nerlynx six tablet day day full dose
tablet dose escal control mention earlier per day first week
per week second week per week start third week second dose
escal cohort evalu nerlynx per day two week per day week
per day thereaft recent start enrol patient prescrib nerlynx dose
escal techniqu first prescript last longer one month would refil first
month cours patient reach daili dose refil frequenc would per
month thu initi dose escal techniqu lead declin bottl sold discontinu
rate declin short-term hit sale could recov patient remain full
dose longer believ key increas nerlynx sale lower discontinu rate think
control trial particular dose escal cohort could give doctor rel easi way
lower incid grade diarrhea consequ discontinu rate think puma
explan lower bottl sale due use dose escal make sens
trend may continu short term forecast nerlynx sale improv beyond
estim nerlynx sale increas million anoth
million
figur quarterli sale bottl
note nerlynx launch juli
note nerlynx launch juli
compani report wainwright research
opportun metastat breast cancer rapidli approach
accord american cancer societi estim new case invas breast
cancer women along new case ductal carcinoma situ dci expect
diagnos american women averag risk develop breast cancer
lifetim approxim american women american men expect die breast
cancer major due metastat breast cancer approxim
breast cancer tumor over-express protein breast cancer often aggress
type breast cancer puma current evalu nerlynx sever trial includ trial
evalu nerlynx neoadjuv therapi patient breast cancer nerlynx approv
extend adjuv therapi patient earli stage breast cancer
australia canada argentina singapor market size third-lin metastat breast cancer
approxim patient patient fourth-lin women earli stage
breast cancer develop metastat breast cancer median age diagnosi breast cancer
women although metastat breast cancer difficult cure improv surviv
shown system treatment median surviv affect subtyp tumor site
metastat involv burden metastat diseas main object treatment metastat
breast cancer prolong patient surviv amelior symptom improv qualiti life patient
symptom metastat breast cancer includ constant back bone joint pain difficulti urin
numb weak constant dri cough short breath difficulti breath chest pain loss
appetit abdomin bloat pain tender constant nausea vomit weight loss jaundic sever
headach vision problem seizur loss balanc confus diagnosi metastat breast
cancer entail blood test whole-bodi bone scan mri spine brain ct scan chest
abdomen pelvi and/or brain pet scan x-ray ultrasound abdomen chest bronchoscopi
constant cough troubl breath present biopsi tap remov fluid symptom area
suggest test repeat upon diagnosi case dispar express
primari site metastas therapi may need alter due statu predict
respons treatment metastat breast cancer sever factor come play import
factor predict treatment respons patient metastat breast cancer hormon receptor
statu overexpress standard-of-car metastat breast cancer first-lin
set taxan docetaxel plu herceptin perjeta two monoclon antibodi roch
rhhbi rate second-lin standard-of-car roch drug kadcyla show orr
month phase emilia trial third-lin standard-of-car tykerb
nala studi could expand label nala puma random multi-cent multi-n open-
label phase trial evalu nerlynx plu roch drug xeloda nucleosid metabol inhibitor
treatment adjuv colon cancer metastat colorect cancer metastat breast cancer versu
tykerb plu xeloda treatment third- later-lin metastat breast cancer primari
endpoint trial independ assess progress free surviv overal surviv os
secondari endpoint trial includ investig assess orr durat respons
dor puma present data nala data show six
month nerlynx plu xeloda versu six month tykerb plu xeloda use pre-
specifi mean analysi mean nerlynx arm month month tykerb
plu xeloda os month nerlynx plu xeloda versu month tykerb plu xeloda
overal cumul incid brain metastas nerlynx arm versu
tykerb arm tykerb sale million million outsid
figur overal surviv nala trial third-lin mbc
saura et al neratinib capecitabin versu lapatinib capecitabin patient metastat
breast cancer previous treat regimen find multi-national random
phase nala trial american societi clinic oncolog annual meet
figur progress free surviv nala trial third-lin mbc
saura et al neratinib capecitabin versu lapatinib capecitabin patient metastat
breast cancer previous treat regimen find multi-national random phase
nala trial american societi clinic oncolog annual meet
buy fein current evalu tucatinib small molecul tki treatment
local advanc unresect metastat breast cancer random
double-blind placebo-control activ compar pivot trial patient trial previous receiv
herceptin perjeta kadcyla patient enrol brain metastas
trial met primari endpoint month tucatinib combin herceptin xeloda
shown superior herceptin xeloda alon reduct risk diseas progress
death tucatinib arm improv os reduct risk death versu
herceptin xeloda alon tucatinib arm reduct risk diseas
progress death versu herceptin xeloda alon patient brain metastas baselin
tucatinib gener well toler trial manag safeti profil diarrhea palmar-plantar
erythrodysesthesia ppe nausea fatigu vomit frequent advers event patient
receiv tucatinib combin herceptin xeloda advers event lead discontinu
occur patient tucatinib arm patient control arm tucatinib also
evalu combin kadcyla versu kadcyla alon treatment patient
unresect locally-advanc metastat breast cancer phase trial nda tucatinib
plan submit fda macrogen chattopadhyay buy current
evalu margetuximab monoclon antibodi target tumor phase
sophia trial treatment metastat breast cancer patient data sophia
present annual meet american societi clinic oncolog june sophia
show median month patient treat margetuximab chemotherapi versu
month patient treat herceptin chemotherapi orr patient treat
margetuximab chemotherapi versu patient treat herceptin chemotherapi
cutoff date octob treatment arm show compar safeti profil grade
advers event occur patient treat margetuximab chemotherapi versu
patient treat herceptin chemotherapi seriou advers event occur
patient margetuximab arm versu herceptin arm infus relat reaction mostli
grade common patient margetuximab arm versu patient
herceptin arm octob second sophia interim analysi data releas show
intent-to-treat popul median os month patient treat margetuximab
chemotherapi versu month patient receiv herceptin chemotherapi safeti
profil second interim analysi compar profil previous report studi
result grade advers event occur patient receiv margetuximab versu
herceptin patient seriou advers event occur patient receiv margetuximab versu
herceptin patient infusion-rel reaction occur patient receiv
margetuximab versu patient receiv herceptin
puma phase trial evalu nerlynx combin kadcyla treatment
metastat breast cancer kadcyla target therapi compris herceptin conjug emtansin
kadcyla approv fda treatment metastat breast cancer previous
treat herceptin taxan chemotherapi kadcyla also approv fda earli stage
breast cancer patient surgeri residu diseas found neoadjuv treatment
herceptin taxan chemotherapi interim result metastat breast
cancer patient previous receiv kadcyla perjeta phase portion trial
evalu efficaci show orr patient enrol time data
present show grade diarrhea report six patient grade nausea three patient
grade thrombocytopenia four patient grade hypertens three patient
one dlt occur dose three dlt occur dose two dlt
occur dose dlt occur dose ten patient diarrhea
manag loperamid prophylaxi trial continu enrol patient data expect
puma on-going phase studi tbcrc evalu nerlynx monotherapi
combin therapi agent treatment metastat breast cancer patient
brain metastas notabl nerlynx plu xeloda alreadi includ nccn guidelin brain
metastas trial non-random open-label trial primari endpoint trial
estim total enrol patient four cohort cohort consist patient receiv
nerlynx cohort consist patient receiv surgic resect cohort compris cohort
includ patient prior tykerb treatment receiv nerlynx plu xeloda cohort
includ patient prior tykerb treatment receiv nerlynx plu xeloda cohort trial
separ three part cohort consist subject previous untreat brain metastas
receiv nerlynx plu kadcyla cohort consist patient progress brain metastas receiv
nerlynx plu kadcyla cohort consist subject progress brain metastas prior kadcyla
treatment receiv nerlynx plu kadcyla cohort show orr
grade toxic occur patient diarrhea patient discontinu
treatment due toxic cohort show orr
puma submit supplement nda third-lin metastat breast cancer fda june
accept septemb fda confirm action date late april
anoth metastat trial puma phase nefertt trial nefertt evalu nerlynx
combin taxol versu herceptin combin taxol frontlin treatment metastat
breast cancer believ potenti patient could potenti address
nala studi repres signific opportun nerlynx near term expect approv
pdufa date late april studi could continu broaden opportun
foreign partnership ad valu capit puma
puma sign multipl intern partnership nerlynx grant market author
european commiss septemb april puma enter exclus
licens agreement pierr fabr privat french compani known breast cancer drug
navelbin vinorelbin pierr fabr grant develop commerci right nerlynx
within europ exclud russia ukrain within part africa agreement pierr fabr
respons conduct addit clinic studi lead regulatori activ european
medicin agenc ema stipul agreement pierr fabr paid puma million up-front
requir provid addit regulatori commerci mileston payment total
million puma would also entitl receiv signific double-digit royalti high nerlynx
sale territori pierr fabr right decemb puma announc
agreement pierr fabr amend extend exclus right nerlynx middl east south
africa sudan turkey agreement stipul puma receiv up-front payment
million addit regulatori sales-bas mileston total million pierr fabr
expect launch nerlynx germani austria launch rest europ
expect take place
novemb puma partner specialis therapeut asia privat grant exclus
right nerlynx throughout south east asia begin australia singapor malaysia brunei
new zealand term agreement gave puma up-front payment mileston payment
total million throughout term agreement double-digit royalti nerlynx sale
licens agreement specifi region march announc specialis
therapeut receiv regulatori approv nerlynx australia decemb announc
specialis receiv market approv nerlynx singapor
scienc author hsa februari puma enter exclus licens agreement
canbridg life scienc privat agreement grant canbridg exclus develop
commerci right nerlynx mainland china taiwan hong kong macau per agreement
puma receiv up-front payment million becam elig potenti mileston
payment million upon achiev certain regulatori mileston puma also entitl
receiv double-digit royalti nerlynx sale greater china potenti mileston payment upon
achiev certain sales-bas mileston novemb nerlynx approv hong
kong nerlynx also expect receiv regulatori approv china taiwan march
puma enter exclus agreement medison pharma privat requir medison
respons regulatori approv israel follow approv commerci nerlynx
israel partnership agreement grant puma right receiv mileston payment double-digit
royalti nerlynx sale israel agreement puma receiv up-front payment
medison approv nerlynx israel expect juli puma partner knight
therapeut khtrf rate exclus canadian commerci nerlynx
agreement puma could potenti receiv up-front mileston payment million
double-digit royalti net sale nerlynx canada puma also partnership pint pharma
privat cover latin america south america region pint pharma grant
exclus right commerci nerlynx argentina brazil chile colombia mexico rest
latin america term agreement puma entitl receiv up-front payment
potenti regulatori commerci mileston payment million double-digit royalti
nerlynx sale latin america pint pharma august pint pharma receiv approv nerlynx
argentina approv nerlynx chile peru expect addit approv nerlynx
mexico columbia brazil ecuador expect believ intern opportun
nerlynx misunderstood ignor investor project intern royalti could significantli
contribut puma beyond
figur outsid approv launch
regulatori approv launch date
expect launch europ
expect approv peru
mexico brazil colombia
note none compani mention publicli trade
compani report wainwright research
potenti expans solid tumor offer anoth opportun
puma conduct basket trial nerlynx call summit studi drug sever solid tumor
summit open-label multicent non-random phase trial evalu efficaci safeti
nerlynx patient erbb mutation-posit gene-amplifi solid tumor mutat
found present approxim nearli everi solid tumor mutat cancer puma
evalu nerlynx monotherapi biliari tract cervic salivari solid tumor
mutat bladder cancer patient summit treatment consist nerlynx plu taxol puma treat
hr breast hr- breast lung colorect cancer nerlynx plu herceptin patient solid
tumor treat nerlynx monotherapi data mutat patient
receiv nerlynx monotherapi present american associ cancer research
meet subsequ publish natur data cutoff date march interim
efficaci result show lung cancer patient orr clinic benefit rate
median month colorect cancer patient clinic benefit
rate median month bladder cancer patient clinic benefit rate
median month safeti data patient report grade diarrhea
median durat grade diarrhea two day four patient perman discontinu treatment due
diarrhea temporarili discontinu treatment temporarili diarrhea subsid summit
loperamid prophylaxi manag led diarrhea treatment-limit side effect april
puma announc summit expand two addit cohort expand cohort includ
patient egfr exon mutat patient metastat salivari gland cancer
cohort design enrol approxim patient
figur design summit basket trial
puma present updat interim data biliari tract cohort summit trial esmo world
congress gastrointestin cancer poster present juli highlight nerlynx
efficaci data biliari tract cancer patient patient enter trial median two
prior system regimen efficaci data show confirm orr clinic benefit rate
biliari tract patient cohort median month regard safeti patient
grade diarrhea grade diarrhea
phase data summit cohort evalu nerlynx combin faslodex
hr metastat breast cancer patient present sabc san antonio texa
cohort patient receiv nerlynx daili plu faslodex label dose patient
receiv median three prior line therapi metastat set enter trial
patient receiv prior faslodex treatment efficaci evalu patient
patient object respons pr also clinic benefit rate
eight patient sd median month median dor month
month safeti data show patient report grade diarrhea patient
perman discontinu nerlynx treatment due diarrhea four patient still treatment
time data report updat data plan present sabc
decemb
recent manag discuss updat interim result summit trial fda regard
regulatori path forward nerlynx treatment mutat cervic cancer mutat
breast cancer updat interim data breast cancer patient show median month
patient treat nerlynx monotherapi median month patient treat
nerlynx plu faslodex median arm nerlynx plu faslodex plu herceptin
reach time report updat data plan present sabc discuss
fda puma decid alter summit trial random er patient receiv
either faslodex faslodex plu herceptin nerlynx combin faslodex plu herceptin
arm plan enrol seven patient first stage follow addit patient one
patient respond per trial protocol first arm stop enrol patient respond also per
protocol four patient expand arm respond enrol ceas expand
four patient respond puma plan schedul pre-nda meet date
fda initi result simon trial order discuss potenti
acceler approv er breast cancer
march updat data summit trial cohort metastat cervic
cancer patient receiv nerlynx announc plenari session societi gynecolog
oncolog annual meet honolulu hawaii data patient advanc and/or
metastat diseas treat nerlynx monotherapi patient median two prior regimen
enter trial orr cervic cancer cohort clinic benefit rate
pr sd week safeti data consist safeti data report
metastat breast cancer grade diarrhea occur patient one grade diarrhea event
occur cohort median month abstract recipi sgo
presidenti award compani plan enrol addit patient mutat cervic cancer
nerlynx monotherapi arm manag plan use data acceler approv file
cervic cancer discuss file acceler approv pre-nda meet
sometim
current model revenu solid tumor indic part summit trial
continu look data believ ultim nerlynx could approv one
indic pay particular attent possibl approv er
base price target price-to-earnings multipl ep estim discount
discount rate use well compani wacc believ price-to-earnings multipl
averag peer appropri project compani turn profit
cash level million end enabl compani reach profit
without revisit capit market
factset rate wainwright research compani report
regulatori risk regulatori risk puma exist futur plan clinic studi could
result signific advers event toxic side effect seen nonclin studi
efficaci outcom could inferior expect may inhibit regulatori approv addit
healthcar reform countri may impact potenti commerci sale
commerci risk commerci risk puma success market sell nerlynx
addit indic drive sale may come fruition diarrhea side effect need better
address order increas sale
clinic develop risk development risk associ nerlynx fail work
expect puma current investig nerlynx sever clinic trial expand indic
multipl trial develop plan stage addit outcom trial
difficult predict could fail number reason includ safeti efficaci requir
regulatori approv indic
manufactur risk third-parti contract manufactur reli upon formul manufactur
nerlynx drug candid agreement would need implement commerci
product futur puma could face issu time cost abil manufactur consist
product manufactur facil highli regul subject risk closur delay
financi risk current puma outstand debt default payment could
caus creditor exercis remedi compani collater compani might need rais
capit futur sustain oper addit stock biotechnolog compani like publicli
trade compani subject market volatil liquid risk small trade float
liabil risk puma certain execut offic current engag sever lawsuit
defend includ one lawsuit total damag estim anoth lawsuit
damag potenti high liabil legal verdict expens nine month end
septemb estim total damag payabl matter relat
side effect properti could result legal action taken subject trial commerci
patient compani product liabil lawsuit common biopharmaceut industri
compani also vulner typic busi liabil associ conduct busi litigi
intellectu properti risk puma portfolio includ patent patent applic
exclus licens issu patent pend patent applic biotechnolog industri litigi
lawsuit consid normal part busi court might uphold puma intellectu
properti right could find puma infring upon anoth parti properti right addit biotech
firm could potenti find loophol puma intellectu properti estat might enabl
launch gener version puma product prior expir patent protect puma unabl
obtain protect intellectu properti right compani may abl compet effect
compani report wainwright estim
licens royalti revenue- total oper expens sell gener research total oper loss incom expens interest incom interest legal verdict expenses- loss debt extinguishment- expense- total net deem dividend convert prefer shareholders- net loss attribut common net loss per share basic weighted-averag common share outstand basic fy puma inc
compani report wainwright estim
assetscash cash market securities- account receiv prepaid expens current defer rent- current assets- total current leas right-of-us assets- properti equip intang asset restrict prepaid expens total liabil stockhold equitycurr liabilitiesaccount payabl accru leas liabilities- total current defer leas liabil long-term- post-market commit liability- long-term total total stockhold equiti total liabil stockhold equiti fy puma inc
compani report wainwright estim
fy flow oper activ net incom adjust reconcil net loss net cash use oper activ depreci stock-bas dispos properti equipment- loss debt extinguishment- debt modif fees- chang oper asset liabil account receiv prepaid expens current assets- account accru post-market commit liability- defer net cash use oper flow invest activ intang purchas properti expenditur leasehold improvements- purchas available-for-sal sale available-for-sale-securities- matur net cash provid use invest flow financ activ net proce issuanc common stock- net proce share issu employe stock proce long-term payment debt- payment debt extinguish costs- payment debt issuanc net cash provid financ net increas decreas cash cash cash equival cash equival begin cash equival end puma inc
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
rate price target histori inc pbyi-u
rate price target histori inc biib-u
rate price target histori inc mgnx-u
rate price target histori inc sgen-u
rate price target histori inc vrtx-u
relat compani mention report
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl decemb
 wainwright co llc firm member finra sipc regist broker-deal
edward white certifi view express report accur reflect person view
subject secur issuer discuss part compens directli indirectli relat
specif recommend view express research report neither member household
offic director advisori board member compani
none research analyst research analyst household financi interest secur puma
inc inc inc inc inc includ without
limit option right warrant futur long short posit
novemb neither firm affili benefici class common equiti secur
inc inc inc inc
neither research analyst firm know reason know materi conflict interest time
public research report
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens inc non-invest bank servic
firm affili receiv compens inc inc inc
invest bank servic within twelv month seek compens
compani mention report invest bank servic within three month follow public research
firm affili receiv compens inc invest bank servic within twelv month
seek compens compani mention report invest bank servic within three
month follow public research report
 wainwright co llc manag co-manag public offer secur inc past
firm make market inc inc inc inc
date research report
secur compani discuss report may unsuit investor depend specif invest
object financi posit past perform guarante futur result report offer inform
purpos constitut offer solicit buy sell secur discuss herein jurisdict
would prohibit research report intend provid tax advic use provid tax advic
person electron version wainwright co llc research report made avail client simultan
part report may reproduc form without express permiss wainwright co llc addit
 wainwright co llc provid individu tailor invest advic research report research report
intend provid person invest advic take account specif invest object financi
situat particular need specif person investor seek financi advic regard appropri
invest financi instrument implement invest strategi discuss recommend research report
 wainwright co llc affili salespeopl trader profession may provid oral written market
commentari trade strategi reflect opinion contrari opinion express research report
 wainwright co llc affili offic director employe exclud analyst time time
long short posit act princip buy sell secur deriv includ option warrant
thereof cover compani refer research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani industri secur
discuss report opinion estim includ report constitut analyst judgment date
report subject chang without notic
secur financi instrument discuss research report may lose valu insur feder
deposit insur corpor subject invest risk includ possibl loss princip amount invest
